U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07847021) titled 'A Multicenter Observational Study of Daridorexant in the Treatment of Insomnia' on Sept. 17.
Brief Summary: This study aims to evaluate the effectiveness and safety of daridorexant, a novel dual orexin receptor antagonist (DORA), in patients with insomnia. The study population consists of patients aged 18 years and older who present with core insomnia symptoms as defined in the Chinese Guidelines for the Diagnosis and Treatment of Insomnia (2023 Edition); eligible patients will receive daridorexant for 16 weeks and will be followed up for improvement in insomnia symptoms and for the occurrence of adverse events, so as to provide re...